Mid-cap biotechnology company United Therapeutics ( UTHR) develops products for patients with infectious and chronic diseases as well as cancer.
Risk management is crucial, however.
Don't count this big bank out after earnings -- shares are showing a bullish price setup in the long-term.
A proxy battle is getting the headlines, but the chart says buy now.
Charts show why these two energy giants won't rally in July.